

# (12) International Application Status Report

**Received at International Bureau:** 20 June 2018 (20.06.2018)

**Information valid as of:** 19 November 2018 (19.11.2018)

**Report generated on:** 26 March 2019 (26.03.2019)

**(10) Publication number:**

WO2018/225830

**(43) Publication date:**

13 December 2018 (13.12.2018)

**(26) Publication language:**

Japanese (JA)

**(21) Application Number:**

PCT/JP2018/021901

**(22) Filing Date:**

07 June 2018 (07.06.2018)

**(25) Filing language:**

Japanese (JA)

**(31) Priority number(s):**

2017-113289 (JP)

**(31) Priority date(s):**

08 June 2017 (08.06.2017)

**(31) Priority status:**

Priority document received (in compliance with PCT Rule 17.1)

**(51) International Patent Classification:**

G01N 33/574 (2006.01); G01N 33/53 (2006.01)

**(71) Applicant(s):**

UNIVERSITY OF MIYAZAKI [JP/JP]; 1-1, Gakuen Kibana-dai Nishi, Miyazaki-shi, Miyazaki 8892192 (JP) *(for all designated states)*

OSAKA UNIVERSITY [JP/JP]; 1-1, Yamadaoka, Suita-shi, Osaka 5650871 (JP) *(for all designated states)*

**(72) Inventor(s):**

NAKAZATO, Masamitsu; c/o Faculty of Medicine, UNIVERSITY OF MIYAZAKI, 5200, Kihara, Kiyotake-cho, Miyazaki-shi, Miyazaki 8891692 (JP)

MATSUMOTO, Nobuhiro; c/o Faculty of Medicine, UNIVERSITY OF MIYAZAKI, 5200, Kihara, Kiyotake-cho, Miyazaki-shi, Miyazaki 8891692 (JP)

TSUBOUCHI, Hironobu; c/o Faculty of Medicine, UNIVERSITY OF MIYAZAKI, 5200, Kihara, Kiyotake-cho, Miyazaki-shi, Miyazaki 8891692 (JP)

ARIMURA, Yasuji; c/o Faculty of Medicine, UNIVERSITY OF MIYAZAKI, 5200, Kihara, Kiyotake-cho, Miyazaki-shi, Miyazaki 8891692 (JP)

YANAGI, Shigehisa; c/o Faculty of Medicine, UNIVERSITY OF MIYAZAKI, 5200, Kihara, Kiyotake-cho, Miyazaki-shi, Miyazaki 8891692 (JP)

TAKAO, Toshifumi; c/o OSAKA UNIVERSITY, 1-1, Yamadaoka, Suita-shi, Osaka 5650871 (JP)

OKUMURA, Nobuaki; c/o OSAKA UNIVERSITY, 1-1, Yamadaoka, Suita-shi, Osaka 5650871 (JP)

**(74) Agent(s):**

UNIUS PATENT ATTORNEYS OFFICE; First Shin-Osaka MT Bldg. 2nd Floor, 5-13-9 Nishinakajima, Yodogawa-ku, Osaka-shi, Osaka 5320011 (JP)

**(54) Title (EN):** LUNG CANCER DETECTION METHOD

**(54) Title (FR):** PROCÉDÉ DE DÉTECTION DU CANCER DU POUMON

**(54) Title (JA):** 肺がんの検出方法

**(57) Abstract:**

**(EN):** Provided is a lung adenocarcinoma detection method that is simple and is less invasive. The lung adenocarcinoma detection method of the present invention includes the step of detecting the presence or absence of an abnormal cleavage in kininogen I in a sample collected from a subject *in vitro*. The abnormal cleavage in kininogen I is, for example, a cleavage that can form at least one cleaved site in a peptide bond in kininogen I and/or a cleavage that causes the deletion of at least one amino acid residue at at least one site in kininogen I. The lung adenocarcinoma detection method according to the present invention includes the step of detecting the presence or amount of a protein having the above-mentioned abnormal cleavage or the loss of the amount of a normal protein, and the like.

**(FR):** La présente invention concerne un procédé de détection d'un adénocarcinome pulmonaire qui est simple et moins invasif. Le procédé de détection d'adénocarcinome pulmonaire de la présente invention comprend l'étape de détection de la présence ou

l'absence d'un clivage anormal dans le kininogène I dans un échantillon collecté à partir d'un sujet *in vitro*. Le clivage anormal dans la kininogène I est, par exemple, un clivage qui peut former au moins un site clivé dans une liaison peptidique dans le kininogène I et/ou un clivage qui cause la délétion d'au moins un résidu d'acide aminé à au moins un site dans le kininogène I. Le procédé de détection d'adénocarcinome pulmonaire selon la présente invention comprend l'étape de détection de la présence ou la quantité d'une protéine comportant le clivage anormal mentionné ci-dessus ou la perte de la quantité d'une protéine normale, et similaire.

**(JA):** 簡易で侵襲性が低い肺腺がんの検出方法を提供する。本発明の肺腺がんの検出方法は、被検体由来試料におけるキニノーゲン I の不正常な切断の有無をインビトロで検知する工程を含む。このようなキニノーゲン I の不正常な切断は、例えば、キニノーゲン I におけるペプチド結合に 1 以上の切れ目をもたらす切断および / またはキニノーゲン I の 1 以上の箇所に、1 または 2 以上のアミノ酸残基の欠損をもたらす切断である。本発明の肺腺がんの検出方法は、このような不正常な切断のあるタンパク質の存在または量、あるいは、正常なタンパク質の量の減少を検知する工程などを含む。

#### **International search report:**

Received at International Bureau: 10 September 2018 (10.09.2018) [JP]

#### **International Report on Patentability (IPRP) Chapter II of the PCT:**

Not available

#### **(81) Designated States:**

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM